3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
12
Cetuximab
9
pembrolizumab
7
Radiotherapy
7
Fluorouracil
6
Carboplatin
5
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
epacadostat
3
Radiation
3
Docetaxel
3
Venlafaxine Hydrochloride
2
Surveys and Questionnaires
2
Panitumumab
2
Paclitaxel
2
Ketamine
2
zimberelimab
1
vandetanib
1
tislelizumab
1
temsirolimus
1
ruxolitinib
1
plerixafor
1
nimotuzumab
1
linrodostat
1
fosbretabulin
1
fluoromisonidazole
1
fludarabine phosphate
1
fludarabine
1
elgemtumab
1
ebselen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Head and Neck Neoplasms
×
fosbretabulin
×
Clear all
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn